Fulton Bank’s Sarepta Therapeutics SRPT Stock Holding History

Fulton Bank’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,165	Closed	-$258K	–	435
2019 Q1	$258K	Buy	+2,165	New	+$278K	0.02%	342

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fulton Bank's SRPT Position: Q2 2019 in Review

Fulton Bank sold out of Sarepta Therapeutics (SRPT) in Q2 2019, closing a stake of 2,165 shares — an estimated $258K sold.

Fulton Bank first reported a position in SRPT in Q1 2019 and held it in 1 quarter. The position peaked at $258K in Q1 2019. 365 funds tracked by Wall St. Rank hold SRPT as of Q2 2019.

Fulton Bank reported no remaining Sarepta Therapeutics position as of Q2 2019 after selling out during the quarter.
Fulton Bank sold 2,165 Sarepta Therapeutics shares in Q2 2019, an estimated $258K.
Fulton Bank first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 1 quarter.
Fulton Bank's Sarepta Therapeutics position peaked at $258K in Q1 2019.
365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2019.

Based on Fulton Bank's 13F filing for Q2 2019, filed 3 Jul 2019.